Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Viloxazine · Qelbree, SPN-812

Small molecule · Inhibitor of norepinephrine transporter (SLC6A2) · developed by Supernus Pharms

Approved FDA, Apr 2021
SUPN Developer
3 Registered trials

What is Viloxazine?

Viloxazine is a selective norepinephrine reuptake inhibitor that blocks the norepinephrine transporter, increasing norepinephrine signaling. It is studied in attention-deficit/hyperactivity disorder (ADHD) and in healthy lactating women.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Qelbree, SPN-812
Drug type
Small molecule
Targets
norepinephrine transporter (SLC6A2)
Mechanism
Inhibitor of norepinephrine transporter (SLC6A2)
Pathways
norepinephrine reuptake
Therapy area
Psychiatry
Developer
Supernus Pharms (SUPN)
FDA status
Approved as Qelbree (April 2, 2021), NDA211964 · FDA label
UNII
5I5Y2789ZF

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06185985 Phase 4 Attention-Deficit/Hyperactivity Disorder Completed SUPN
NCT06259331 Phase 4 Healthy Lactating Women Completed SUPN
NCT01107496 Phase 1/2 Attention-Deficit/Hyperactivity Disorder (ADHD) Completed SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Attention-Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactivity Disorder (ADHD)Healthy Lactating Women

Other drugs acting on SLC6A2

More from Supernus Pharms

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.

Follow SUPN, the company behind Viloxazine

See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SUPN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.